A 15-year-old girl was admitted to the New England Medical Center Hospital (NEMCH) for investigation of the hypothalamic-pituitary axis. Four years earlier, an eosinophilic granuloma was discovered in the left mandible and was treated with excision and irradiation (1,000 rads). Two years earlier she developed polyuria, and a diagnosis of diabetes insipidus was made at another hospital. She was treated with synthetic lysine vasopressin nasal spray (Diapid) several times a day and noted some symptomatic improvement. Eighteen months before admission, her menstrual periods, which had been normal for the previous 14 months, ceased and she complained of cold intolerance, constipation, and weight gain. She claimed to have grown '/2 inch over the year prior to admission. She had occasional mild headaches when she did not take her medication but noted no visual disturbances. Family history was unrevealing. Her mother was 5 ft 1 inch tall.
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Physical examination revealed the following findings: blood pressure, 110/70; heart rate, 60/mm; weight, 51.5 kg; height, 5 ft 2 inch; skin was pale and dry; optic fundi were normal; formal testing for visual fields revealed no defects; there was a pale, white lesion on the inner aspect of the right-lower jaw; the thyroid gland was not palpable; breast development was stage III to IV; rectal examination was normal; neurological examination was normal.
Laboratory findings revealed the following data: hematocrit, 39%; white blood cell count, 6,700 with a normal differential; erythrocyte sedimentation rate, 10 mm/br; urine sediment, unremarkable; blood urea nitrogen (BUN), 12 mg; serum creatinine, 1 mg; serum calcium, 10.8 mg; serum phosphorus, 3.6 mg/l00 ml; serum electrolytes were normal; the chest radiogram was normal; both bone scan and gallium scan revealed an area of increased uptake over the right mandible.
Various tests of hypothalamic-pituitary function revealed the following: an elevated resting prolactin level; a low T3 and T41 572 with an inappropriately low level of thyroid-stimulating hormone (TSH); an inappropriately low level of lute inizing hormone (LH) for a patient with amenorrhea; a decreased growth hormone response to insulin infusion; and a normal cortrosyn stimulation test. Both TSH and LH responded normally to infusion of the appropriate releasing hormones. Data from a water deprivation test are shown in Table I .
The lesion in the right mandible was biopsied and again revealed an eosinophilic granuloma. A second course of radiation (800 rads) was delivered to the right mandible on an outpatient basis. She was treated with L-thyroxin (150 pg/day), estrogen, and lysine vasopressin nasal spray.
One year later, lysine vasopressin was discontinued in preparation for the institution of dDAVP (l-desamino-8-D arginine vasopressin) therapy. Urine volume rose promptly to over 10 liters/day, but fell dramatically to less than 1 liter/day in response to dDAVP (15 pg. twice daily, intranasally). A repeat biopsy of the right mandible revealed recurrent eosinophilic granuloma. Cerebral computerized tomographic (CT) scan showed a questionable shift of the third ventricle and deformity of the basal cisterns. Pneumoencephlogram revealed a slight flattening of the infundibular recess of the third ventricle and asymmetry of the optic chiasm, but these findings were judged to be probably normal. Visual field examination was again normal. Repeat insulin tolerance test and an arginine infusion test revealed normal growth hormone responses. The right mandibular lesion was surgically excised; no further radiation was given. The patient has been evaluated biannually and continues to do well 2 years later. The dose of dDAVP has been reduced to 15 pg in the morning and 10 pg in the evening. She is asymptomatic and plans to pursue a career in nursing. Medical Services, Massachusetts General Hospital): Neurogenic diabetes insipidus is a clinically rare but physiologically important disturbance of water balance. Its pathophysiology is as clearly understood as is any aspect of renal physiology and endocrine homeostasis. It results from a failure of antidiuretic hormone (ADH) secretion in response to the physiologic stimulus of water deficiency. This is the condition that our patient has and for which she exhibits all the classical and essential diagnostic criteria.
Since the classic studies of Verney [1] in the mid1940s, it has been evident that the neurohypophysis plays a fundamental role in the economy of body fluids and in the regulation of the tonicity of the body fluids. This it does in combination with the thirst mechanism as established a decade later by Andersson [2] . The resulting "double negative" feedback system which sustains our serum sodium concentrations constant between some 136 and 143 mEq/liter and the corresponding serum osmolality between 275 and 290 mosm/kg of water is shown in Figure 1 . Cell membranes are generally so permeable to water that a single tonicity-chemical potential of water-exists throughout all body fluid compartments. Thus this neurohypophysis-thirstrenal axis accounts for the constancy of serum sodium concentration and of osmolality of intracellular as well as extracellular fluids. It is so effective that the range of values that we accept as normal probably represents largely analytical rather than biologic variation.
With loss of neurohypophyseal function the situation changes as shown in Figure 2 . Thus, even when the ADH limb of the "double negative" regulatory feedback is lost, the thirst mechanism still preserves a serum sodium and osmolality within the normal range but at the expense of pronounced polydipsia and polyuria. It is true that statistically the serum sodium concentration or osmolality of an untreated patient with diabetes insipidus may be slightly higher than the mean normal value, but the range of the latter prevents such small increases from having any diagnostic significance. Thus Barlow and de Wardner [3] found the plasma osmolality of patients suffering from diabetes insipidus to average 295 15 mOsm!kg of water (SD), whereas that for normal subjects averaged 280 6 mOsmlkg of water (SD). Since this statistically significant difference is associated with considerable overlap this determination is of little help diagnostically in the individual patient.
When unconsciousness or lack of water occurs, however, the patient with diabetes insipidus will continue to lose water with resulting weight loss and increase in serum osmolality. Dehydration of a serious degree can occur rapidly in such circumstances. This sequence is depicted nicely in the provocative diagnostic tests shown for our patient in Table I . When fluids were withheld after 10 p.m., the bladder contained a large volume of urine the following morning. The hourly urine flow remained high, its concentration fell to minimal levels, the patient lost weight, and her serum osmolality increased from a normal level of 283 to 309 mOsm/kg of water. The values show good internal consistency since the patient lost 2.2 kg during the 14 hours of water restriction and had a negative fluid balance by urine losses alone of 2.01 kg; her serum osmolality increased thereby to 309 mOsm/kg whereas the theoretical expected final osmolality would be some 305 mOsm/kg, assuming an initial Nephrogenic diabetes insipidus is congenital, makes its appearance shortly after birth, occurs predominantly in males, and appears to result from genetic deficiency of adenylate cyclase responsive to ADH in the renal tubules. The other three conditions usually show stigmata of the disease or disturbance causing them and should not be difficult to diagnose.
Other provocative tests have been utilized in the diagnosis of diabetes insipidus. Infusion of hypertonic saline to elevate serum osmolality and thus to provide the stimulus for ADH release has been used, as has pharmacologic stimulation of ADH release with nicotine. The simple overnight dehydration test, however, as applied to this patient is by far the most satisfactory diagnostic test. Nonetheless, one must be aware that in the youngster with presumptive diabetes insipidus dangerous levels of negative water balance may develop rapidly; thus, urine volumes and weight must be followed carefully to avoid serious consequences of dehydration. Similar precaution must be exercised in testing the obtunded or mentally confused adult. A more troublesome differential diagnosis occasionally exists in relation to primary polydipsia. polyd psia (29) (7) (3) (2) Diabetes insipidus is itself a benign condition so long as adequate water, or replacement therapy, or both is available. Because loss of neurohypophyseal function however may have different etiologies, not all of which are benign, it is important to learn if possible the cause in each case. Randall has suggested an etiologic classification of diabetes insipidus with two major categories, primary and secondary [5] . Primary diabetes insipidus includes familial and idiopathic cases. Idiopathic cases constitute the major group in any such classification, comprising 45% of Blotner's series [6] but perhaps exceeded today by head injuries, iatrogenic or accidental. Idiopathic diabetes insipidus may become manifest at any age and may affect either sex. It is unusual for the idiopathic type to appear early in infancy, as does nephrogenic diabetes insipidus, although it may develop in childhood. Familial diabetes insipidus, on the other hand, is very uncommon and constitutes less than 1% of cases. It may become manifest in infancy and may affect either sex. The condition has been described in seven generations of one family [7] .
In the group with secondary diabetes insipidus, head trauma-accidental or neurosurgical-and neoplasms-primary or metastatic-constitute the major causes. In older series, primary intracranial tumors constituted nearly one-third of all cases. The currently increasing incidence of automobile injuries, surgical pituitary stalk sections, and other neurosurgical procedures in the neighborhood of the neurohypophyseal system has affected the frequency of secondary diabetes insipidus. Of the metastatic tumors, breast cancer and lung cancer seem to have special predilection for the hypothalamus. Other etiologic factors contribute only small numbers to any series. However, sarcoidosis, birth injuries, eosinophilic granuloma-as our patient has-and a variety of local infections appear on any listing of extensive causes of diabetes insipidus.
Even with disease or tumor within the hypothalamus, diabetes insipidus is unusual. With loss or destruction of the posterior pituitary gland, diabetes insipidus may be short lived or nonexistent because the active hormone, which is synthesized in the supraoptic nuclei and to a lesser degree in the paraventricular nuclei, is transmitted down the supraopticohypophyseal tract and stored for release in the posterior pituitary. The hormone can be released from the higher levels of the tract when lower portions are damaged or destroyed, thus preventing manifest diabetes insipidus.
This capability of higher levels within the hypothalamus to subsume the secretion of ADH when lower portions of the supraopticohypophyseal tract have been damaged was described by Fischer, Ingram, and Ranson [8] in experimental diabetes insipidus and probably accounts for the variable clinical course. I have seen complete diabetes insipidus following head trauma, which after maintaining a flagrant course for 3 years subsided, with replacement therapy no longer needed and with return of concentrating ability. On the other hand, I have seen diabetes insipidus start at 1 p.m. on a Saturday Nephrology Forum afternoon, cease abruptly 2 weeks later, and never return! Given the evidence from biopsies of the mandible, we can presume that eosinophilic granuloma is the cause of diabetes insipidus in the patient under discussion today. Eosinophilic granuloma is frequently multifocal, often involves the mandible, and may affect both the bones and viscera. In the brain, the hypothalamus is most commonly affected but sometimes the cerebellum and cortex are involved. A lesion in the hypothalamus in our patient would account not only for the diabetes insipidus but also for the other endocrine changes elicited by the provocative tests of hypothalamic-pituitary function.
Thus, the elevated resting prolactin level is consistent with loss of the hypothalamic prolactin inhibitory factor (PIF). The low peripheral thyroid hormone levels and low level of the pituitary thyroid-stimulating hormone (TSH) is consistent with decreased or absent hypothalamic thyrotropin releasing hormone (TRH). The normal response of TSH to infusion of TRH confirms the hypothalamus as the site of the primary deficiency. The low level of LH and its normal response to infusion of luteinotrophin releasing hormone (LRH) has the same interpretation as does the diminished growth hormone response to hypoglycemic stress, which points to a deficiency of hypothalamic growth hormone releasing factor (GHR). All of these tests indicate a lesion of the hypothalamus. The normal cortrosyn stimulation test of the adrenal cortex is reassuring evidence that glucocorticoid function is adequate. Although adrenal insufficiency may result from eosinophilic granuloma, we had strong evidence of normal adrenal cortical function in this patient from the observation that she could elaborate large volumes of very dilute urine. This capability is lost with adrenal or anterior pituitary failure even in the presence of neurogenic diabetes insipidus, though the mechanism of the lost ability to excrete a copious dilute urine with loss of both ADH and adrenal cortical secretions is still not well understood.
Although the function of this exercise is to discuss the disturbance in water metabolism, a word should be said regarding the patient's underlying problem, multifocal eosinophilic granuloma-a very confusing clinical entity or entities! Multifocal eosinophilic granuloma often makes its first appearance as a bony lesion of the mandible, mastoid, or skull. But when diabetes insipidus is the first manifestation, it is caused by granulomas within the hypothalamus, as in our patient, and not by pressure from adjacent bony tumors. Other soft tissue organs, such as the liver, spleen, lymph nodes, and skin, may also be involved. Evidence for cerebral and cerebellar dysfunction may also be present. Anterior pituitary failure rarely develops in the course of this enigmatic disease, but whether this complication is the result of loss of hypothalamic trophic factors or direct destruction of the anterior pituitary by granuloma has not been settled by either hormone assays or postmortem studies to my knowledge.
Treatment of eosinophilic granuloma by surgical excision or radiation of local solitary bone lesions is usually successful. In multifocal eosinophilic granuloma beneficial results have been reported with chemotherapy including vinbiastine, prednisone, mercaptopurine, or methotrexate singly or in various combinations. Once the diabetes insipidus is established, however, it does not respond to treatment of the underlying eosinophilic granuloma.
Finally, a word should be said regarding the therapy of diabetes insipidus. The condition has no known deleterious effect on health so long as its cause is benign and so long as water is available, the subject is conscious, and the thirst center is functioning. Thus, the indications for replacement therapy may not be pressing. The marked polyuria and polydipsia with complete lack of ADH activity usually is disturbing and socially distressing during the day and may interfere with sleep at night. For reasons of convenience and comfort replacement therapy is usually justified. Fortunately, several modes of therapy are available. A variety of ADH sprays and powders for intranasal insuffiation, as well as ADH for injection, have been the standard replacement therapy. Lysine vasopressin spray provides control of polyuria for relatively short periods of 2 to 6 hours, insufficient for an undisturbed night's sleep. Moistening a pledget of cotton, however, with the solution of hormone and inserting it into a nostril at bed time is used by some to obtain an undisturbed night. Pitressin tannate in oil (5 U/mI) is potent and effective for 24 to 72 hours. It requires a deep subcutaneous or intramuscular injection by a fairly large gauge needle because of the viscosity of the oil vehicle. This material causes sterile abscesses in some subjects. Care must be taken to allow return of polyuria and polydipsia between injections in order to avoid cumulative water retention and severe hyponatremia. The main drawbacks of pitressin tannate are, however, the discomforts and inconvenience attended upon any preparation that must be adminisNeurogenic diabetes insipidus 577 tered parenterally. Aqueous vasopressin (20 pressor units per ml), when it is available, plays virtually no role in the management of chronic diabetes insipidus. It does allow a readily controllable method of treating the comatose patient with head trauma and polyuria when the pitressin is diluted and administered intravenously. Since aqueous pitressin is degraded very rapidly its action ceases within minutes after the infusion is stopped. This property makes it worthless in the management of chronic diabetes insipidus. One young patient of mine had a sister who was a nurse. The sister injected the patient subcutaneously with 1 ml of the aqueous hormone preparation four times daily-a total of 80 pressor units! With each injection the patient experienced general abdominal and uterine cramps, perioral blanching, and 30 to 60 minutes of decreased urine output. Later we found that 2 units of pitressin administered as the long-acting pitressin tannate in oil controlled her symptoms for over 24 hours.
In the mid-1960s, structure-activity investigations were performed in Czechoslovakia with a variety of synthetic analogues of vasopressin [91. From these studies emerged a substituion of D for L arginine at position 8 which resulted in a peptide, DAVP, with diminished vasopressor activity. Deamination of the hemicystein at position 1 gave rise to a second peptide, dAVP, with enhanced antidiuretic to pressor activity and prolonged duration of action. Combining both changes in one molecule, that is, deamination at position 1 and substitution of D for L arginine in position 8 results in a peptide, dDAVP, with high antidiuretic to pressor potency (approximately 2000:1) and a prolonged duration of action (6 to 24 hours), as compared with the natural hormone AVP (AD:P = 1) and duration of action (2 to 4 hours) [10, 11] . This compound, dDAVP, is available for administration intranasally, and the experience to date indicates it to be a safe and effective means of control. Generally, administration twice daily in doses as low as 5 to 20 suffices in many patients. Local nasal irritation and systemic reactions are rare. An occasional patient may complain of headaches, and that is about all the side reactions that have been noted. The medication is readily self-administered intranasally by a plastic catheter (Rhinyle®; A. B. Ferring Company, Malmo, Sweden).
Though intranasal dDAVP is the treatment of choice for diabetes insipidus, it is well to remember that alternatives to hormone replacement may be helpful at times. Since, with a very dilute urine of fixed osmolality, the urine volume is determined by the solute load requiring excretion, a reduction chiefly of salt and protein in the diet will reduce the major urinary solutes and thus the volume of urine necessary to accommodate their excretion. A diuretic such as chlorothiazide administered chronically will maintain a state of mild sodium depletion which impairs "free water" excretion by the kidneys and thus reduces urine volume from distressing levels of 6 to 10 liters daily to volumes of 2 to 4 liters. Chlorpropamide seems to potentiate the action of even small amounts of circulating antidiuretic hormone and may thereby enhance antidiuresis when neurohypophyseal failure is not complete. Severe hypoglycemia may be a complicating aspect of this therapy and is especially harmful in the young patient. Thus, dDAVP by intranasal administration seems today the safest and most effective form of therapy for this distressing condition.
Questions and Answers DR. SEYMOUR REICHLIN (Chief, Endocrinology, NEMCH) : We assessed the location of the lesion in this patient to be precisely where you did. It is really the only site where a small lesion can destroy antidiuretic function and some, but not all, anterior pituitary functions without producing other gross physiologic abnormalities [12] . A very small lesion is responsible it seems. DR. J. J. COHEN: Dr. Reichlin, considering the propensity of lesions such as this to recur and to grow, is it surprising to you that the patient has not shown more evidence of difficulty over a rather long period of time? Is it safe to follow a patient in this fashion?
DR. S. REIcHLIN: it has been difficult to decide how to manage this patient. The possibility of an expanding granulomatous mass in the hypothalamus that might produce progressive damage has concerned us because some cases have been reported in which rapid expansion of an eosinophilic granuloma has caused death. On the other hand, we feel we can monitor the lesion by the use of the CT scan and by careful clinical evaluation. We have been concerned about exposing the hypothalamus to a tumorcidal dose of radiation and thus endangering the patient's residual hypothalamic function. We have been on the horns of a dilemma, that is, to produce further damage versus protect her from tumor growth. We have elected to follow a con- DR. A. LEAF: I can refer you to the excellent study by Fischer, Ingram, and Ranson [8] . They produced stereotactic lesions in cats and found that the animals went through several phases. Immediately after surgery there was a very intense antidiuresis, then a phase in which polyuria occurred and was followed by mild antidiuresis, and finally permanent diabetes insipidus developed if the lesion was produced in the right location. They attributed the initial antidiuresis to release of stored hormone and the subsequent polyuria and mild antidiuresis to a period of decreased hormone availability. The final permanent diabetes insipidus resulted if a lesion had been produced that prevented further hormone secretion. They found that even if they transsected the supraopticalhypophyseal tract low down, the mamillary bodies in the hypothalamus could actually take over the hormone secretion; thus, the posterior pituitary could be destroyed and yet permanent diabetes insipidus not develop. I think the slow recovery that sometimes occurs is due to the subsiding of the response to the trauma in the higher portions of the tract. This restoration allows the hormone to be released at higher levels, closer to the supraoptic nuclei where it is formed. That is my interpretation of the physiologic events when recovery is delayed as long as a year.
DR. J. J. COHEN: There is convincing evidence that volume "receptors" and other nonosmolar factors also control ADH release. Do the osmolar and nonosmolar mechanisms operate through the same neurons or are there different pathways involved? Also, do nonosmolar factors affect hormone synthesis or just hormone release? DR. S. REICHLIN: The supraoptic neuron is played upon by a variety of impulses. The opiates should be mentioned because recent evidence indicates that endorphins activate the supraoptic neurons directly. This mechanism apparently accounts for morphine-induced antidiuresis. These very same neurons are responsive to acetylcholine, which mediates the right auricular and volume controls. They are also responsive to norepinephrine and to both sodium shifts and osmotic changes. Angiotensin II also appears to act directly on supraoptic neurons. This provides a mechanism through which decreased blood volume could signal ADH release. The osmoreceptor area contains integrating cells, the membranes of which process a great deal of neurotransmitter information from all parts of the body: blood chemistry, volume receptors, and probably psychological data as well. They are impressively versatile neurons. DR. J. J. COHEN: I was trying to determine whether all cells in this area serve this integrating function or whether separate cells have different roles, which in the aggregate give rise to the observed, integrated behavior.
DR. S. REICHLIN: It has not been possible to answer that question with confidence because the best data are obtained by placing an electrode into the neuron itself. Hayward [13] found that a certain proportion of such cells will discharge repetitively when hypertonic saline is injected into the carotid artery.
DR. NIcoLAos E. MADIAS (Renal Service, NEMCH): Could you comment on recent observations that show a linkage between ADH and prostaglandins; namely, that ADH stimulates the production of prostaglandins, and that prostaglandins antagonize the hydroosmotic effect of ADH [14] [15] [16] [17] . A study in the Brattleboro rat shows that the excretion of prostaglandin E2 is very low and that it increases significantly after injection of ADH [14] . Do you envision a role for this system in the diagnosis and treatment of diabetes insipidus? DR. A. LEAF: I think this area needs more exploration. You described the state of the art as well as I know it in your comments: ADH seems to effect the synthesis of prostaglandins by releasing arachiadonic acid and evoking synthesis. There are many potentials for interplay that must have some physiologic and clinical significance, but they need to be developed.
DR. J. P. KASSIRER: We've seen in recent years an explosion in the number of drugs that have notable effects on water balance. Some, in particular chlorpropamide, appear to have some important therapeutic properties. What are the current thoughts on the mechanism of action of chiorpropamide? DR. A. LEAF: I haven't studied chiorpropamide myself. Two studies have described differing physiologic mechanisms at work, One study in the toad bladder demonstrated evidence that chlorpropamide potentiates the effects of small amounts of ADH on the permeability to water [18] . Another study argued that the drug caused the release of ADH from the neurohypophysis [19] . The presence of ADH seems to be necessary for chiorpropamide to work. If there is still some residual function, that effect may be of therapeutic value. I think today with other modes of therapy available it is probably advisable not to use chlorpropamide, particularly in children because of the risk of hypoglycemia.
DR. WILLIAM E. COBB (Endocrinology, NEMCH): Several patients have been described in the literature with diabetes insipidus and absolute diminished thirst. Some have had essential hypernatremia, high sodium levels, and no response to osmotic stimuli. It has been suggested that chlorpropamide is probably the drug of choice for treating this group of patients. It has also been suggested that perhaps chiorpropamide has an effect on the thirst center. Do you know of any data that would support this hypothesis? DR. A. LEAF: I don't. I think that this entity does not result from a single etiology. I think that it is possible to have a lesion in the hypothalamus that destroys the neurons responsible for thirst and also those responsible for osmoregulation. Though these neurons are apparently separable, both centers are located close together in the lateral preoptic and supraoptic areas of the anterior hypothalamus, respectively. I have no experience with possible effects of chlorpropamide on thirst or its use in these very rare cases.
DR. J. P. KASSIRER: Dr. Cobb, would you elaborate a bit on your studies of therapy with a synthetic analogue of vasopressin? DR. W. E. COBB: As Dr. Leaf mentioned before, dDVAP has a longer duration of action and a much higher antidiuretic to pressor potency than the parent compound, AVP. We studied intranasal dDAVP in 29 patients with chronic and 2 patients with acute-that is, postoperative -diabetes insipidus [20] . Twenty-eight patients with chronic neurogenic diabetes insipidus, who have now been followed for up to 35 months, achieved excellent control of symptoms at a dose of 2.5 to 15.0 g, once every 8 to 24 hours. One patient, initially well controlled on 10 tg, twice daily, developed partial resistance to dDAVP and presently requires a dose of 15 to 20 g, four times daily. Headache occurred in the "resistant" patient at high doses (over 20 tg) and in one additional patient at a dose of 10 In each of two patients who developed acute diabetes insipidus after transfrontal removal of a craniopharyngioma, 5 tg intranasal dDAVP every 14 to 18 hours was effective. We have not used dDAVP to treat acute diabetes insipidus after transsphenoidal hypophysectomy because of surgically induced contusion and swelling of nasal mucus membranes.
In patients with chronic diabetes insipidus, dDAVP resulted in a degree of control superior to that of chlorpropamide or lysine vasopressin nasal spray and as good as that obtained with vasopressin tannate in oil. The frequent occurrence of side effects with chlorpropamide-hypoglycemia, reactions similar to those seen with antabuse-and vasopressin tannate in oil-sterile abscesses, abdominal pain-especially in children, was in marked contrast to the low frequency and minor nature of side effects with dDAVP. We feel that intranasal dDAVP is the preferred treatment of chronic diabetes insipidus in both children and adults, and of acute postoperative diabetes insipidus following transfrontal surgery. Hopefully, the cost of this drug will fall in the near future and thus make it possible to exploit its advantages more widely.
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